Pharmacokinetic crossover trials on GelShield Extended-Release Metformin gut tolerability, topical Diclofenac patch RCTs for targeted joint relief without GI bleeding, and Phase 3 biologic clearance trials in psoriasis and autoimmune disease. Explore 546 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
MC-003 outperformed NS in reducing the need for additional injections during en bloc resection, particularly in larger lesions located in the distal portion of the stomach (where most lesions were found) during ESD procedures,...
Supplementing with synbiotics exhibits promising neuroprotective and therapeutic effects in the treatment of Parkinson's disease patients.
After septorhinoplasty, the administration of 1000 mg of IV paracetamol demonstrated comparable efficacy in pain reduction to 30 mg of ketorolac.
This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52.
This trial indicates that ketotifen may offer a promising approach for preventing OIPN.
Although the JOQUER trial reported no overall benefit from HCQ in pSS patients, stratification suggests that.
FMT with or without metformin significantly improve insulin resistance and body mass index and gut microbial communities of T2DM patients by colonization of donor-derived microbiota.
The results highlight whey protein's potential as a nutritional aid to promote recovery and physiological adaptation, possibly mediated by antioxidant and anti-inflammatory mechanisms.
Iontophoresis using tretinoin and tacrolimus was found to be effective and safe for the treatment of PPP.
Exit interviews were conducted with 29 of 159 patients enrolled in XTEND-1 (mean [range] age 40 [16-73] years).
Rosuvastatin exposure was moderately higher with filgotinib getting both at the same time-GLSM ratios (90% CI), 1.68 (1.43-1.97) for C max ; 1.42 (1.30-1.57) for AUC inf -but this was not considered clinically relevant.
Conclusion: Meloxicam IV was generally well tolerated and associated with decreased opioid consumption, lower resource utilization and functional benefits.
The safety profile of upadacitinib through 5 years was consistent with the known safety profile of upadacitinib, with no new safety risks.
We also found that the impact of other treatments on hair regrowth is very uncertain.
The addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for...
Ozoralizumab demonstrated significant therapeutic effects and efficacy, which was maintained for 52 weeks.
LB 133 mg administered via sciatic nerve block in the popliteal fossa after bunionectomy demonstrated superior and long-lasting postsurgical pain control versus BUPI.
Etretin showed equivalent efficacy to that previously reported with etretinate in severe recalcitrant plaque psoriasis skin flare-ups skin flare-ups vulgaris.
Nevertheless, eight weeks after therapy had been stopped, six (32%) of 19 patients had cholesterol values that were still 20% or more above their baseline levels; the prolonged etretinate excretion time could have been...
PPV with SO tamponade significantly reduces recurrent infection and intraocular inflammation in severe postoperative endophthalmitis, leading to trends toward improved visual outcomes.
Procedural difficulty of minor complications during surgery, postsurgical complications, and additional/corrective procedures were infrequent, although more common with tanezumab 5mg, typically occurring in patients.
Six months of TRT improved body composition in men with opioid-induced hypogonadism without significant changes in outcomes of pain perception, quality of life, or adrenal function.
These results demonstrate that EE/CA+metformin treatment reduced inflammation markers in cases with PCOS compared to EE/CA treatment.
GRF6019 demonstrated excellent safety, feasibility, and tolerability.
The safety profile remained consistent with the safety profiles noted in previous risankizumab studies.
During the OLE of SAkuraSky, 16 patients tapered steroids and the ARR did not increase from the DB period.
The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values ( p p < 0.05).
Addition of ezetimibe to a moderate weight loss diet in obese subjects can significantly improve liver steatosis, inflammation, and LDL-apoB-100 metabolism.
Etrasimod was efficacious in improving symptoms of UC from week 2; improvements were maintained through week 52.
This may be due to better staying on track with medication in the study environment or patients' preference for the spray vehicle.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
